Abstract
One reason for the failure of chemotherapy in the treatment of advanced cancers may be the outgrowth of multidrug-resistant tumour cells1–5. Multidrug resistance has been modelled in numerous mammalian cell lines in which the phenotype is characterized by a pleiotropic cross-resistance to unrelated drugs1–7. In the study reported here, we have produced monoclonal antibodies whose binding to plasma membranes of different multidrug-resistant mammalian cells correlates with the degree of drug resistance. All these antibodies are specific for P-glycoprotein, a cell surface component of relative molecular mass (Mr) 170,000 (170K) that has been described previously8–15, and are directed against three spatially distinct epitopes which define a conserved cytoplasmic domain in the C-terminal region of the P-glycoprotein polypeptide. The conserved nature of P-glycoprotein and its low-level expression in drug-sensitive cells suggest that it has an important function at the cell surface. The monoclonal antibodies against P-glycoprotein described here might serve as diagnostic reagents for clinically unresponsive tumours16.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ling, V. in Drug Resistance and Neoplasia Vol. 1 (eds Bruchovsky, N. & Goldie, J. H.) 1–19 (CRC Press, Florida, 1982).
Ling, V., Gerlach, J. & Kartner, N. Breast Cancer Res. Treat. 4, 89–94 (1984).
Curt, G. A., Clendeninn, N. J. & Chabner, B. A. Cancer Treat. Rep. 68, 87–99 (1984).
Riordan, J. R. & Ling, V. in The International Encyclopedia of Pharmacology and Therapeutics (ed. Goldman, I. D.) (Pergamon, New York, in the press).
Biedler, J. L. & Peterson, R. H. F. in Molecular Actions and Targets for Cancer Chemotherapeutic Agents (eds Sartorelli, A. C., Lazo, J. S. & Bertino, J. R.) 453–482 (Academic, New York, 1981).
Kaye, S. & Merry, S. Cancer Chemother. Pharmac. 14, 96–103 (1985).
Beck, W. T. Adv. Enzyme Regul. 22, 207–227 (1984).
Juliano, R. L. & Ling, V. Biochim. biophys. Acta 455, 152–162 (1976).
Juliano, R., Ling, V. & Graves, J. J. supramolec. Struct. 4, 521–526 (1976).
Riordan, J. R. & Ling, V. J. biol. Chem. 254, 12701–12705 (1979).
Kartner, N., Shales, M., Riordan, J. R. & Ling, V. Cancer Res. 43, 4413–4419 (1983).
Kartner, N., Riordan, J. R. & Ling, V. Science 221, 1285–1288 (1983).
Giavazzi, R., Kartner, N. & Hart, I. R. Cancer Chemother. Pharmac. 13, 145–147 (1984).
Ling, V., Kartner, N., Sudo, T., Siminovitch, L. & Riordan, J. R. Cancer Treat. Rep. 67, 869–874 (1983).
Debenham, P. G., Kartner, N., Siminovitch, L., Riordan, J. R. & Ling, V. Molec. cell. Biol. 2, 881–889 (1982).
Bell, D. R., Gerlach, J. H., Kartner, N., Buick, R. N. & Ling, V. J. clin. Oncol. 3, 311–315 (1985).
Riordan, J. R. et al. Nature 316, 817–819 (1985).
Westhof, E. et al. Nature 311, 123–126 (1984).
Tainer, J. A. et al. Nature 312, 127–134 (1984).
Benjamin, D. C. et al. A. Rev. Immun. 2, 67–101 (1984).
Tsuruo, T. Cancer Chemother. Rep. 67, 889–894 (1983).
Rogan, A. M., Hamilton, T. C., Young, R. C., Klecker, R. W. & Ozols, R. F. Science 224, 994–996 (1984).
Ling, V. & Thompson, L. H. J. cell. Physiol. 83, 103–116 (1974).
Bech-Hansen, N. T., Till, J. E. & Ling, V. J. cell. Physiol. 88, 23–31 (1979).
Ling, V. Can. J. Genet. Cytol. 17, 503–515 (1975).
Kuo, T., Pathak, S., Ramagli, L., Rodriguez, L. & Hsu, T. C. in Gene Amplification (ed. Schimke, R. T.) 53–57 (Cold Spring Harbor Laboratory, New York, 1982).
Simard, R. & Cassingena, R. Cancer Res. 29, 1590–1597 (1969).
Langelier, Y., Simard, R. & Brailovsky, C. Differentiation 2, 261–267 (1974).
Giavazzi, R., Scholar, E. & Hart, I. R. Cancer Res. 43, 2216–2222 (1983).
Siegfried, J. M., Tritton, T. R. & Sartirelli, A. C. Eur. J. Cancer din. Oncol. 19, 1133–1141 (1983).
Beck, W. T., Mueller, T. J. & Tanzer, L. R. Cancer Res. 39, 2070–2076 (1979).
Peterson, G. L. Analyt. Biochem. 83, 346–356 (1977).
Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. J. biol Chem. 193, 265–275 (1951).
Gefter, M. L., Margulies, D. H. & Scharff, M. D. Somat. Cell Genet. 3, 231–235 (1977).
Shulman, M., Wilden, C. D. & Köhler, G. Nature 276, 269–270 (1978).
Towbin, H., Staehelin, T. & Gordon, J. Proc. natn. Acad. Sci. U.S.A. 76, 4350–4354 (1979).
Ey, P. L., Prowse, S. J. & Jenkin, C. R. Immunochemistry 15, 429–436 (1978).
Greenwood, F. C., Hunter, W. M. & Glover, J. S. Biochem. J. 89, 114–123 (1963).
Davis, F. M., Tsao, T. Y., Meyers, M. B., Peterson, R. H. F. & Spengler, B. A. Cancer Treat. Rep. 67, 859–867 (1983).
Fairbanks, G., Steck, T. L. & Wallach, D. F. H. Biochemistry 10, 2606–2616 (1971).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kartner, N., Evernden-Porelle, D., Bradley, G. et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316, 820–823 (1985). https://doi.org/10.1038/316820a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/316820a0
This article is cited by
-
Cancer stem cells and strategies for targeted drug delivery
Drug Delivery and Translational Research (2021)
-
Novel features in the structure of P-glycoprotein (ABCB1) in the post-hydrolytic state as determined at 7.9 Å resolution
BMC Structural Biology (2018)
-
Ovarian hormones modulate multidrug resistance transporters in the ovary
Contraception and Reproductive Medicine (2018)
-
Detoxification mechanisms involved in ivermectin resistance in the cattle tick, Rhipicephalus (Boophilus) microplus
Scientific Reports (2018)
-
Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies
Current Hematologic Malignancy Reports (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.